Financings in Brief: Diametrics Medical
This article was originally published in The Gray Sheet
Executive Summary
Diametrics Medical: Blood chemistry testing system manufacturer nets $29.3 mil. in a public offering of 3 mil. shares of its common stock for $10.50 per share. The St. Paul, Minnesota-based firm filed a registration statement for the offering in July ("The Gray Sheet" July 17, p. 31). The funds are tabbed for expanding sales and marketing, boosting manufacturing facilities, research and development of new blood analysis tests for the firm's IRMA system, as well as "general corporate purposes." UBS Securities, Vector Securities International, and Dain Bosworth have 30 days to exercise their 450,000 share over-allotment option, Diametrics says...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.